Vaxxinity (NASDAQ:VAXX) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Vaxxinity (NASDAQ:VAXXGet Rating) from a buy rating to a hold rating in a report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Vaxxinity Inc. is a biotechnology company pioneering a new class of immunotherapeutic vaccines to democratize health. Vaxxinity Inc. is based in DALLAS, Texas. “

Separately, Evercore ISI started coverage on shares of Vaxxinity in a research report on Wednesday, April 27th. They issued an in-line rating on the stock.

VAXX stock opened at $4.50 on Wednesday. Vaxxinity has a 52 week low of $3.04 and a 52 week high of $22.77. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.46 and a quick ratio of 5.46. The business’s fifty day moving average price is $4.37.

Vaxxinity (NASDAQ:VAXXGet Rating) last posted its quarterly earnings data on Thursday, March 24th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.13). On average, analysts forecast that Vaxxinity will post -1.18 earnings per share for the current fiscal year.

In other news, insider Mei Mei Hu acquired 8,038 shares of the firm’s stock in a transaction that occurred on Monday, April 25th. The stock was purchased at an average price of $3.37 per share, with a total value of $27,088.06. Following the purchase, the insider now owns 51,593,454 shares of the company’s stock, valued at approximately $173,869,939.98. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder United Biomedical Inc acquired 18,105 shares of the firm’s stock in a transaction that occurred on Tuesday, April 26th. The stock was purchased at an average cost of $3.45 per share, with a total value of $62,462.25. Following the purchase, the insider now directly owns 51,611,559 shares in the company, valued at approximately $178,059,878.55. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 30,950 shares of company stock worth $106,759.

A number of institutional investors have recently bought and sold shares of VAXX. FNY Investment Advisers LLC acquired a new position in Vaxxinity in the 4th quarter worth approximately $27,000. Virtu Financial LLC acquired a new position in Vaxxinity in the 4th quarter worth approximately $93,000. ETF Managers Group LLC acquired a new stake in shares of Vaxxinity during the 4th quarter valued at $211,000. Geode Capital Management LLC acquired a new stake in shares of Vaxxinity during the 4th quarter valued at $382,000. Finally, Millennium Management LLC acquired a new stake in shares of Vaxxinity during the 4th quarter valued at $489,000. 15.82% of the stock is owned by hedge funds and other institutional investors.

About Vaxxinity (Get Rating)

Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD.

Read More

Get a free copy of the Zacks research report on Vaxxinity (VAXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.